ESR2 and cancer: In summary, our study suggests that short-term treatment of brain endothelial cells with E2, an agonist for both ERα and ERβ, tended to increase cancer cell passage through BBB in vitro models, while treatment with DPN, a selective ERβ agonist, tended to reduce it.